Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Neurobiol Dis. 2019 Jan 30;125:123–134. doi: 10.1016/j.nbd.2019.01.020

Figure 7.

Figure 7.

Combination (COMB) treatment significantly increased sAPPα production and synaptic markers PSD-95 and SNAP-25.

Representative Western blot and densitometry analysis of (a) full length APP (fAPP), sAPPα and sAPPβ, and (b) PSD-95 and SNAP-25 in SH-SY5Y-APP cells treated with etodolac (ETO), α-tocopherol (Tph), and COMB 10μM each for 24 h. Data represented as mean ± SD of 3 independent experiments with n=3 dishes/treatment group/experiment. (c) Representative Western blot and densitometry analysis of fAPP, sAPPα and sAPPβ, and (d) PSD-95 and SNAP-25 expressions in the brain homogenates of 5XFAD mice. Mice were treated with ETO, Tph or COMB at 10 mg/kg/day each for 30 days. Data are presented as mean ± SEM for n=5–6 mice in each group. ns = not significant; * p < 0.05, ** p < 0.01, *** p < 0.001 compared to CTRL; # p < 0.05, ## p < 0.01 represent COMB compared to ETO alone; @ p < 0.05, @@ p < 0.01, @@@ p < 0.001represent COMB compared to Tph alone.